Neurovalens granted FDA medical approval for weight management device
Neurovalens, a global leader in non-invasive neuro-technology, has been granted medical device De Novo approval from the US Food & Drug Administration (FDA) for Modius Lean, its prescribed treatment for weight management.
Based in Belfast, Northern Ireland, Neurovalens is a pioneering medical device company which specialises in leveraging the power of neuroscience and advanced technology to address a variety of global health challenges across a range of at-home treatments in both metabolic and mental health.
The company’s Modius technology uses low-level electrical signals to non-invasively stimulate areas of the brain known to regulate key functions such as the management of sleep, anxiety, and overall metabolic health.
